Address
High-Tech Village Givat-Ram Campus Building 2.4
GG, Jerusalem GG
9270401
Israel
Contact
Niv Bachnoff+972542386023
niv@omnixmedical.com
Website
OMN6 – the Next-Generation of Antibiotic Drugs
OMN6 is a novel antimicrobial peptide developed for IV administration in hospitalized patients suffering from severe or life-threatening infections involving Multi-Drug-Resistant bacteria
OMN6 is effective and safe. Targeting a huge, urgent unmet need, OMN6 eliminates resistan
Technology:
Microorganisms:
Application:
Development stage:
- Infection prevention
- Antimicrobial compounds
- Alternative antimicrobials
- Antimicrobial stewardship
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Fungi
- Yeasts
- Viruses
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Development
- Research
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Joint Venture
- Sell
- Outsource
Funding organisation:
Infectious disease area:
Geographic origin:
Big-pharma or a strategic-player that has the experience and expertise to join us in bringing a life-saving antibiotic drug to the market
Omnix Medical is a privately-owned biotechnology company developing the next-generation antibiotics against Multi Drug Resistant bacteria
Omnix is developing a pipeline of anti-infective compounds at different stages of the development route
